Development of KCC2 therapeutics to treat neurological disorders.

KCC2 is CNS neuron-specific chloride extruder, essential for the establishment and maintenance of the transmembrane chloride gradient, thereby enabling synaptic inhibition within the CNS. Herein, we highlight KCC2 hypofunction as a fundamental and conserved pathology contributing to neuronal circuit excitation/inhibition (E/I) imbalances that underly epilepsies, chronic pain, neuro-developmental/-traumatic/-degenerative/-psychiatric disorders. Indeed, downstream of both acquired and genetic factors, multiple pathologies (e.

A radiation therapy platform to enable upright cone beam computed tomography and future upright treatment on existing photon therapy machines.

Background: The conventional lying down position for radiation therapy can be challenging for patients due to pain, swallowing or breathing issues. To provide an alternative upright treatment position for these patients, we have developed a portable rotating radiation therapy platform which integrates with conventional photon treatment machines. The device enables cone-beam computed tomography (CBCT) imaging of patients in an upright position, and the future delivery of therapeutic radiation.

Self-reported awareness of genetic testing, the impact of family history, and access to clinical trials for people diagnosed with ovarian cancer in Australia.

Objectives: To assess the understanding of people diagnosed with ovarian cancer regarding genetic testing; to understand knowledge gaps among people diagnosed with ovarian cancer that may impact best practice care; and to monitor overall changes in understanding from 2015 to 2022.

Design: Longitudinal 'opt-in' study using an online survey tool at three timepoints: 2015, 2018 and 2022.

Participants: People in Australia (or their families / caregivers) diagnosed with ovarian cancer between 2010 and 2022).